Supreme Extends Due Diligence and Cancels Private Placement

Supreme Pharmaceuticals Inc. (the "Company") (OTCBB:SPRWF)(TSX VENTURE:SL)
reports that the parties to the agreement to acquire the South Okanagan
producing medical marijuana facility, have mutually agreed upon an extension of
the due diligence period to April 29th, 2014.


In addition, the Company has cancelled its plans for the previously announced
private placement.


SUPREME PHARMACEUTICALS INC.

David Stadnyk, President & CEO

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FORWARD LOOKING INFORMATION

This News Release contains forward-looking statements. The use of any of the
words "anticipate", "continue", "estimate", "expect", "may", "will", "project",
"should", "believe" and similar expressions are intended to identify
forward-looking statements. Although the Company believes that the expectations
and assumptions on which the forward-looking statements are based are
reasonable, undue reliance should not be placed on the forward-looking
statements because the Company can give no assurance that they will prove to be
correct. Since forward-looking statements address future events and conditions,
by their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual results could
differ materially from those currently anticipated due to a number of factors
and risks including various risk factors discussed in the Company's disclosure
documents which can be found under the Company's profile on www.sedar.com. This
News Release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Supreme Pharmaceuticals Inc.
David Stadnyk
President & CEO
[phone]
[e-mail]
www.supremepharmaceuticals.com